Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific and CryoCor announce merger agreement
This acquisition follows a development agreement, in place since June 2007, to pursue therapeutic solutions for atrial fibrillation, or ‘Afib’. The acquisition, which has been approved by the
This acquisition follows a development agreement, in place since June 2007, to pursue therapeutic solutions for atrial fibrillation, or ‘Afib’. The acquisition, which has been approved by the
The companies will ensure that patients enrolled in the ongoing Phase II study will continue to receive the current standard of care. ViroPharma also announced that ViroPharma and
Mr Pfeffer will report to Hakan Edstrom, president and COO, and will serve on MannKind’s executive leadership team. Mr Pfeffer’s appointment follows the previously announced retirement of Dick
As part of the collaboration, Xceed and the University of Florida will test approximately 700 samples from patients previously identified to have either cancerous or non-cancerous bladder tumors
In the completed dose-escalation Phase I/II trial, 72 patients with relapsed or refractory CD30-positive lymphoma received weekly doses of MDX-060 (0.1, 1, 4, 10 or 15mg/kg) for four
In this dose-escalating Phase I trial (trial 102), MGCD265 is administered orally to patients at an initial starting dose of 24mg/m2 daily on an intermittent basis (every other
Pursuant to the transaction, Metabasis reduced the exercise prices of the existing warrants held by the participants in exchange for the immediate exercise of the warrants. Metabasis also
Insmed’s INS-19, which is a recombinant form of human G-CSF, is a follow-on biologic of the FDA-approved product Neupogen. Preclinical studies demonstrate that INS-19 and FDA-approved Neupogen are
The contract establishes Holmes Biopharma with another major multinational pharmaceutical company, generating substantial phase I clinical trial revenue for the Omaha operation. Furthermore, this contract is a significant
Under the terms of the agreement, Galapagos will pay Enceladus an upfront fee and run the clinical development of Nanocort. Enceladus will receive a minority share of future